This Quality Enhancement Research Initiative (QuERI) is a knowledge translation medical practice activity based on decision making support through feedback to physicians on their management of dyslipidemia in order to achieve guidelines recommended LDL-C levels in high risk patients. Physician interaction has three distinct components: 1. Capture of data as reported by participating physician; 2. Highlight (by providing feedback) where management may be optimized based on guidelines or recommendations; 3. Identify challenges faced by physicians resulting in the care gap..
The GOAL QuERI International will engage approximately 115 health care practitioners (HCP) who will enroll up to 2500 patients with management observations based on four visits by the patients in an outpatient setting. The timing of the visits will be baseline, 6±2 months, 12±2 months, and 18±2 months during which patient management by their physician will be captured using the electronic data capture form (DCF). The DCF will be created and managed by the CHRC.
Study Type
OBSERVATIONAL
Enrollment
2,422
Cross-Reference
Sabah Hosptial
Kuwait City, Kuwait
Centro de Estudios Clínicos de Querétaro (CECLIQ)
Querétaro City, Querétaro, Mexico
King Fahd Military Medical Complex
Dhahran, Saudi Arabia
Cleveland Clinic
Abu Dhabi, United Arab Emirates
Proportion of patients achieving country specific guideline-recommended LDL-C levels after 18 month final visit or last available observation during follow up visits.
the outcome variable, LDL-C, will be presented with mean and standard deviation
Time frame: LDL-C target after 18 month final visit
1. Relative and absolute reduction of LDL-C with lipid lowering medications added during the observation period.
the outcome variable, LDL-C, will be presented with mean and standard deviation
Time frame: The timing of the visits will be baseline, 6±2 months, 12±2 months, and 18±2 months during which patient management by their physician will be captured using the electronic data capture
Proportion of patients not achieving recommended LDL-C level based on high risk inclusion sub-group (e.g. FH), co-morbid conditions (diabetes mellitus), baseline treatment or baseline lipid profile.
the outcome variable, LDL-C, will be presented with mean and standard deviation
Time frame: The timing of the visits will be baseline, 6±2 months, 12±2 months, and 18±2 months during which patient management by their physician will be captured using the electronic data capture
Proportion of patients not achieving recommended LDL-C level at each of the follow up visits according to physician responses as to why country specific recommendation for LDL-C lowering opportunities was not followed.
the outcome variable, LDL-C, will be presented with mean and standard deviation
Time frame: The timing of the visits will be baseline, 6±2 months, 12±2 months, and 18±2 months during which patient management by their physician will be captured using the electronic data capture
Proportion of patients achieving LDL-C and non-HDL level across participating countries.
the outcome variable, LDL-C, will be presented with mean and standard deviation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: The timing of the visits will be baseline, 6±2 months, 12±2 months, and 18±2 months during which patient management by their physician will be captured using the electronic data capture